| First Author | Lopes N | Year | 2017 |
| Journal | EMBO Mol Med | Volume | 9 |
| Issue | 6 | Pages | 835-851 |
| PubMed ID | 28455312 | Mgi Jnum | J:270980 |
| Mgi Id | MGI:6161992 | Doi | 10.15252/emmm.201607176 |
| Citation | Lopes N, et al. (2017) Administration of RANKL boosts thymic regeneration upon bone marrow transplantation. EMBO Mol Med 9(6):835-851 |
| abstractText | Cytoablative treatments lead to severe damages on thymic epithelial cells (TECs), which result in delayed de novo thymopoiesis and a prolonged period of T-cell immunodeficiency. Understanding the mechanisms that govern thymic regeneration is of paramount interest for the recovery of a functional immune system notably after bone marrow transplantation (BMT). Here, we show that RANK ligand (RANKL) is upregulated in CD4(+) thymocytes and lymphoid tissue inducer (LTi) cells during the early phase of thymic regeneration. Importantly, whereas RANKL neutralization alters TEC recovery after irradiation, ex vivo RANKL administration during BMT boosts the regeneration of TEC subsets including thymic epithelial progenitor-enriched cells, thymus homing of lymphoid progenitors, and de novo thymopoiesis. RANKL increases specifically in LTi cells, lymphotoxin alpha, which is critical for thymic regeneration. RANKL treatment, dependent on lymphotoxin alpha, is beneficial upon BMT in young and aged individuals. This study thus indicates that RANKL may be clinically useful to improve T-cell function recovery after BMT by controlling multiple facets of thymic regeneration. |
